Table 3. Competing Risk Regression Analysis for Atrial Fibrillation in NSCLC Cohort.
| Variablea | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | P value | aHR (95% CI) | P value | |
| SAN Dmax, Gy | ||||
| <20.0 | 1 [Reference] | NA | 1 [Reference] | NA |
| ≥20.0 | 13.15 (1.73-99.82) | .01 | 15.67 (2.08-118.20) | .008 |
| Age, y | 1.03 (0.97-1.09) | .30 | NA | NA |
| Sex | ||||
| Male | 1 [Reference] | NA | NA | NA |
| Female | 0.53 (0.13-2.25) | .39 | NA | NA |
| ECOG performance status | ||||
| 0 | 1 [Reference] | NA | NA | NA |
| 1-2 | 2.64 (0.35-19.96) | .35 | NA | NA |
| Tobacco use | ||||
| Never | 1 [Reference] | NA | 1 [Reference] | NA |
| Ever | 5.15 (0.71-37.7) | .11 | 5.07 (0.74-34.71) | .10 |
| Alcohol use | ||||
| Never | 1 [Reference] | NA | NA | NA |
| Ever | 0.63 (0.25-1.63) | .34 | NA | NA |
| Hypertension | ||||
| No | 1 [Reference] | NA | 1 [Reference] | NA |
| Yes | 3.38 (1.19-9.56) | .02 | 3.74 (1.24-11.20) | .02 |
| Diabetes | ||||
| No | 1 [Reference] | NA | NA | NA |
| Yes | 3.08 (1.18-8.02) | .02 | NA | NA |
| Cardiovascular disease | ||||
| No | 1 [Reference] | NA | 1 [Reference] | NA |
| Yes | 0.69 (0.16-2.95) | .61 | 0.33 (0.09-1.28) | .11 |
| Coronary artery calcium | ||||
| No | 1 [Reference] | NA | NA | NA |
| Yes | 4.16 (0.56-31.1) | .16 | NA | NA |
| CAC score | 1.00 (1.00-1.01) | .03 | NA | NA |
| No. of coronary arteries with calcification | ||||
| 0 | 1 [Reference] | NA | NA | NA |
| 1-2 | 2.97 (0.34-26.3) | .33 | NA | NA |
| 3-4 | 4.96 (0.65-37.8) | .12 | NA | NA |
| Aortic valve calcification | ||||
| No | 1 [Reference] | NA | 1 [Reference] | NA |
| Yes | 4.24 (1.64-11) | .003 | 3.18 (1.17-8.67) | .02 |
| Mitral valve calcification | ||||
| No | 1 [Reference] | NA | NA | NA |
| Yes | 2.45 (0.69-8.64) | .16 | NA | NA |
| Pericardial effusion after CRT | ||||
| No | 1 [Reference] | NA | NA | NA |
| Yes | 0.80 (0.11-5.85) | .82 | NA | NA |
| BMI | 1.01 (0.90-1.12) | .89 | NA | NA |
| AJCC stage | ||||
| II-IIIA | 1 [Reference] | NA | NA | NA |
| IIIB-IIIC | 0.94 (0.35-2.54) | .90 | NA | NA |
| Chemotherapy | ||||
| Others | 1 [Reference] | NA | NA | NA |
| Paclitaxel + carboplatin | 0.71 (0.16-3.11) | .65 | NA | NA |
| Maintenance ICI | ||||
| No | 1 [Reference] | NA | NA | NA |
| Yes | 0.91 (0.26-3.15) | .88 | NA | NA |
| RT dose, Gy | 1.05 (0.94-1.17) | .39 | NA | NA |
| RT modality | ||||
| 3D-CRT | 1 [Reference] | NA | NA | NA |
| IMRT | 1.50 (0.55-4.14) | .43 | NA | NA |
Abbreviations: 3D-CRT, 3-dimensional conformal radiotherapy; AJCC, American Joint Committee on Cancer; aHR, adjusted hazard ratio; BMI, body mass index; CAC, coronary artery calcification; CVD, cardiovascular disease; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; HTN, hypertension; ICI, immune checkpoint inhibitor; IMRT, intensity-modulated radiotherapy; NA, not applicable; NSCLC, non–small cell lung cancer; RT, radiotherapy; SAN Dmax, maximum radiation dose exposed to sinoatrial node; WHO, World Health Organization.
a
The categorical variable of chest surgery after CRT had no events in 1 of the subgroups and was not applicable for regression analysis.